A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Clinical trial NCT05074433 · TERMINATED

Trial details

NCT number: NCT05074433
Sponsor: Regeneron Pharmaceuticals
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Immunocompromised

Start date: 2021-10-25
Primary completion: 2022-05-18
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.